Wistar Institute

Engimmune Therapeutics Announces the Appointment of Dr Annalisa D'Andrea to its Board of Directors

Retrieved on: 
Dienstag, Mai 23, 2023
Inflammation, GSK, Antigen, University, Therapy, ARCH Venture Partners, Biotechnology, Cancer, University of Florence, TCR, SRI International, Discovery, Bangladesh Technical Education Board, Publication, Novartis, Patient, Wistar Institute, Drug discovery, Growth, Immunology, University of Siena, Pharmaceutical industry

BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.

Key Points: 
  • BASEL, Switzerland, May 23, 2023 /PRNewswire/ -- Engimmune Therapeutics AG ("Engimmune"), a Swiss biotech company developing novel T-cell receptor (TCR)-based therapeutics, is pleased to announce the appointment of Dr Annalisa D'Andrea to its board of directors as a non-executive director as of the 1 of June 2023.
  • Dr. D'Andrea has over 25 years of experience in the life-science industry including immunology research, drug discovery and development, and strategic leadership in biotechnology and pharmaceutical companies.
  • She is a Venture Partner at Longwood Fund and is the former President and Chief Scientific Officer of ImmuneID.
  • Dr Annalisa D'Andrea, Member of the Board of Directors at Engimmune Therapeutics commented: "I am delighted to be joining Engimmune Therapeutics at an exciting and important phase of development as the Company strives to develop new multi-specific TCR therapies for the treatment and benefit of patients with cancer and autoimmune diseases.

Wistar Scientists Discover Innate Tumor Suppression Mechanism

Retrieved on: 
Donnerstag, Mai 4, 2023
Online, Perelman School of Medicine at the University of Pennsylvania, Database, CRISPR, Human, Cell biology, Ashkenazi Jews, University, Molecule, Life, Fox Chase Cancer Center, University of Kansas, Culture, Neoplasm, Infection, St. Jude Children's Research Hospital, Cancer, American Association for Cancer Research, Biomedical Research, Mutation, Research, Immunotherapy, Ellen, PADI4, Citrulline, Patient, Wistar Institute, Risk, Machine learning, Engineering, Immune system, Ausländer, Paper, Mouse, Artificial intelligence, Gene, TCGA, NIH, African Americans, Genome, Vaccine, Pharmaceutical industry, Medical device, Wistar, Cancer Discovery (journal)

Now, in a recent study published in Cancer Discovery , a journal of the American Association for Cancer Research, researchers at The Wistar Institute have uncovered a key mechanism as to how p53 suppresses tumors.

Key Points: 
  • Now, in a recent study published in Cancer Discovery , a journal of the American Association for Cancer Research, researchers at The Wistar Institute have uncovered a key mechanism as to how p53 suppresses tumors.
  • Publication information: An African-Specific Variant of TP53 Reveals PADI4 as a Regulator of p53-Mediated Tumor Suppression, Cancer Discovery, 2023.
  • Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology.
  • Consistent with its legacy of leadership in biomedical research and a track record of life-saving contributions in immunology and cell biology, Wistar scientists’ early-stage discoveries shorten the path from bench to bedside.

OmniAb Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights

Retrieved on: 
Donnerstag, März 30, 2023
Science, Other Science, Biotechnology, Research, Pharmaceutical, Health, Genetics, Clinical Trials, Apoptosis, Gilead Sciences, Therapy, Progression-free survival, Telephone, Health care, European Medicines Agency, STR, Janssen, Medication, NSCLC, Antibody, Marketing, Sale, Graves' ophthalmopathy, Shanda, Bangladesh Technical Education Board, Investment, Patient, Financial result, European, Wistar Institute, National Medical Products Administration, United Kingdom, Growth, Merck, Teclistamab, Regulation of tobacco by the U.S. Food and Drug Administration, PD-L1, Eurosport 1, Food, Cryptocurrency, Pharmaceutical industry, Video game, EU

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three and 12 months ended December 31, 2022, and provided operating and partner program updates.
  • On November 1, 2022, OmniAb completed a spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ: LGND), resulting in OmniAb becoming an independent publicly traded company.
  • Financial results prior to November 1, 2022, are presented on a carve-out basis derived from Ligand’s historical accounting records, as if OmniAb were an independent company.
  • In 2022, the company signed 13 new licenses, including one in the fourth quarter with the Wistar Institute.

Virion Therapeutics Presents Promising Preclinical Cancer Data When Using a Novel Genetically Encoded Checkpoint Modifier-Based Immunotherapy

Retrieved on: 
Montag, März 6, 2023
Science, MD, Pharming, IND, Death, Infection, Therapy, ESMO, Immunotherapy, Congress, Cancer, HBV, Wistar Institute, Vaccine, Virus

Top line results, following a single intramuscular injection of this novel immunotherapy include:

Key Points: 
  • Top line results, following a single intramuscular injection of this novel immunotherapy include:
    "Glycoprotein D (gD), when genetically expressed as a fusion protein with antigen(s) of choice, enhances, broadens, and prolongs CD8+ T cell responses.
  • In this preclinical model of fast-growing HPV-16-associated tumors, a gD-based immunotherapy against HPV-16 provided incredibly strong protection against tumor growth and death," said Hildegund Ertl, MD, Professor, Vaccine & Immunotherapy Center, at The Wistar Institute in Philadelphia PA and Scientific Co-Founder of Virion Therapeutics.
  • "These preclinical oncology data demonstrated treatment responses which were profound, durable, and reproducible - and show clear differentiation to any other immunotherapy or vaccine in development.
  • The above presentation is available via the ESMO TAT meeting website, https://www.esmo.org/meeting-calendar/esmo-tat-2023/, and on Virion's website at https://www.viriontx.com/science/presentations-publications/ .

Wistar Scientists Identify a Gene Signature to Assess Cancer Risk in People

Retrieved on: 
Montag, Februar 6, 2023
Online, Machine learning, Research, Culture, Marker beacon, Wistar Institute, Cancer, Infection, NIH, Cell biology, Molecule, Biomedical Research, Environment, TP53, T32, Vaccine, PNAS, Wistar

This does not help people determine whether they have increased cancer risk.

Key Points: 
  • This does not help people determine whether they have increased cancer risk.
  • This knowledge could be used to screen individuals with genetic variants of p53 and better inform them of their cancer risk and response to therapy.
  • Publication Information: Common activities and predictive gene signature identified for genetic hypomorphs of TP53.
  • Wistar scientists are focused on solving some of the world’s most challenging and important problems in the field of cancer, infectious disease, and immunology.

Wistar Institute HIV Researchers Win Grant to Explore Genetically Engineered Natural Killer Cells as HIV Therapy

Retrieved on: 
Donnerstag, Januar 19, 2023
Wistar, Wistar Institute, HIV/AIDS research, AIDS, HIV, Immunotherapy, Canadian Foundation for AIDS Research, NK, HIV/AIDS, Cancer, Montaner, Antibody, AmfAR, NIH, Vaccine, Research

Montaner, who leads The Wistar Institute’s HIV Research Program, is studying the ability of a type of immune cell known as natural killer (NK) cells to kill HIV-infected cells.

Key Points: 
  • Montaner, who leads The Wistar Institute’s HIV Research Program, is studying the ability of a type of immune cell known as natural killer (NK) cells to kill HIV-infected cells.
  • “This grant to Dr. Montaner is the latest of several awards we have made to outstanding scientists at The Wistar Institute,” said Dr. Rowena Johnston, amfAR’s Vice President and Director of Research.
  • These strategies will be combined and tested in mouse models with functional human immune cells able to support HIV infection.
  • The Montaner lab and other groups in the BEAT-HIV Collaboratory were awarded a five-year award from the NIH last year.

Wistar Institute’s Maureen Murphy Named Deputy Director of the Ellen and Ronald Caplan Cancer Center

Retrieved on: 
Freitag, Januar 13, 2023
Molecule, National Cancer Institute, NCI, Wistar Institute, Rutgers University, Education, Biochemistry, Doctor of Philosophy, Perelman School of Medicine at the University of Pennsylvania, Colorectal cancer, Biomedical Research, Molecular biology, Culture, University of Michigan Rogel Cancer Center, HSP70, Arnold, Drexel University College of Engineering, Infection, University, History, Growth, Survival, Therapy, Drexel University College of Medicine, Fox Chase Cancer Center, Research, Cancer, Ellen, Science, Faculty, Princeton University, Cell biology, Pharmaceutical industry, Management, Wistar

PHILADELPHIA, PA, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Maureen Murphy, Ph.D. , has been named Deputy Director of the Ellen and Ronald Caplan Cancer Center at The Wistar Institute.

Key Points: 
  • PHILADELPHIA, PA, Jan. 13, 2023 (GLOBE NEWSWIRE) -- Maureen Murphy, Ph.D. , has been named Deputy Director of the Ellen and Ronald Caplan Cancer Center at The Wistar Institute.
  • In 2022 Wistar became the first basic NCI-designated Cancer Center to earn the Cancer Center Support Grant Merit Extension .
  • The Ellen and Ronald Caplan Cancer Center was formally named in 2022 and prioritizes the prevention and treatment of cancer by advancing fundamental high-risk, high-reward basic science into next-generation therapeutics.
  • Prior to joining Wistar, Murphy was a professor at the Fox Chase Cancer Center.

IMUNON Enters into Collaborative Research Agreement with The Wistar Institute’s Vaccine & Immunotherapy Center to Research IMUNON’s PLACCINE Vaccine Platform

Retrieved on: 
Donnerstag, Januar 5, 2023
Cancer, Organic acid, Research, DNA, Wistar Institute, Infection, Heart, Wistar, Immunity, Biomedical Research, Vaccine, Pharmaceutical industry

IMUNON’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems.

Key Points: 
  • IMUNON’s platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems.
  • “We are delighted to enter into this collaborative research agreement with The Wistar Institute Vaccine & Immunotherapy Center, possessing world renowned expertise in cancer, immunology, infectious diseases, and vaccine creation.
  • Wistar is uniquely positioned to advance new vaccine formulations in collaboration with IMUNON,” said Dr. Corinne Le Goff, President and Chief Executive Officer of IMUNON.
  • “This collaboration will facilitate further expansion and development of PLACCINE with the goal of expanding vaccine targets ideally matched for our novel formulated DNA delivery platform and further optimizing quality attributes and the immunity of products.”

FIVE ORGANIZATIONS PARTNER TO DESIGN NEW BIOTECH TRAINING PROGRAM TO CONNECT PHILADELPHIANS WITH QUALITY JOBS IN THE REGION'S RAPIDLY GROWING LIFE SCIENCES SECTOR

Retrieved on: 
Dienstag, August 23, 2022
Workforce, CEO, Science, Program, Doctor of Philosophy, Wistar Institute, University City, Philadelphia, Associate, Human resources, Hope, Senior, BTT, Foundation, Wistar, Philadelphia Naval Shipyard, Ecosystem, Growth, Industry, Employment, Medicine, Iovance Biotherapeutics

PHILADELPHIA, Aug. 23, 2022 /PRNewswire/ -- Partners in Greater Philadelphia's life sciences ecosystem are collaborating to create a new workforce development training model to connect biotech jobs with a wider range of Philadelphians, including residents from disadvantaged communities. In a field that often requires PhDs or master's degrees for most roles, the program – "Biomedical Technician Training Program: Aseptic Manufacturing" – will create opportunities for Philadelphians with at least a high school equivalency. The initiative is one way the region is working together to meet the talent needs in its rapidly growing cell and gene therapy sector.

Key Points: 
  • In a field that often requires PhDs or master's degrees for most roles, the program "Biomedical Technician Training Program: Aseptic Manufacturing" will create opportunities for Philadelphians with at least a high school equivalency.
  • The initiative is one way the region is working together to meet the talent needs in its rapidly growing cell and gene therapy sector.
  • For the West Philadelphia Skills Initiative, which has extensive experience developing training programs with healthcare organizations, the entry into life sciences is an exciting evolution.
  • "Iovance is proud to be a part of the vibrant, diverse Greater Philadelphia community and rapidly growing cell therapy hub.

Finding HIV's Sweet Spot

Retrieved on: 
Dienstag, Juli 5, 2022
Cell, Memory, Wistar Institute, National, Media contacts database, Communication, University of California, San Francisco, Tcell, Roan, Protein, Tissue, AIDS, Biomarker, Infection, Population, UM1, Center, Blood, HIV, SAN, Bias, Fucose, CyTOF, Moore v. Regents of the University of California, Technology, University, Sugar, Antibody, Doctor of Philosophy, Virus, Urology, Cell biology, Gladstone Institutes, HIV/AIDS, Research, Severe acute respiratory syndrome coronavirus 2, HIV/AIDS research, Multimedia, Lectin, Collection, Vaccine, Pharmaceutical industry, Antibiotics, ELife, William Ewart Gladstone

SAN FRANCISCO, July 5, 2022 /PRNewswire/ -- HIV researchers have long been trying to identify the specific cells that the virus prefers to infect and hide in. They know that HIV favors a special type of immune cells called memory CD4 T cells. But these cells come in many flavors, and it has been difficult to ascertain exactly what makes one type of memory CD4 T cell more attractive to HIV than another.

Key Points: 
  • Together, the scientists uncovered surprisingly different sugar patterns on different immune cells, and an intriguing interplay between HIV and the sugars coating CD4 Tcells.
  • The work also showcases a new technique for studying individual cells from large populations that could lead to a more detailed picture of cellular diversity.
  • Encouraged by this finding, the scientists next applied CyTOF-Lec to CD4 Tcells that they had first exposed to HIV in the lab.
  • To ensure our work does the greatest good, Gladstone Institutes focuses on conditions with profound medical, economic, and social impactunsolved diseases.